Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Mole101on Mar 19, 2021 1:44pm
144 Views
Post# 32838995

RE:RE:FOMO !

RE:RE:FOMO !

House positioning taking place ...

From:  To:  


5,019,119 ($1,683,312) AGN.CN shares exchanged hands from Mon Mar 15 2021 to Fri Mar 19 2021.

House  Bought  Sold  Net 
House 080
National Bank
Bought $419,628
Volume 1,237,830
Average $0.339
Sold $117,209
Volume 355,041
Average $0.330
Net $302,419
Volume 882,789
 
House 001
Anonymous
Bought $812,479
Volume 2,430,310
Average $0.334
Sold $550,038
Volume 1,640,172
Average $0.335
Net $262,441
Volume 790,138
 
House 017
Integral
Bought $13,801
Volume 41,000
Average $0.337
Sold 0
Volume 0
Average 0
Net $13,801
Volume 41,000
 
House 013
Instinet
Bought $11,619
Volume 35,000
Average $0.332
Sold 0
Volume 0
Average 0
Net $11,619
Volume 35,000
 
House 143
Pershing
Bought $11,723
Volume 35,000
Average $0.335
Sold $5,484
Volume 16,378
Average $0.335
Net $6,239
Volume 18,622
 
House 036
Latimer
Bought $5,609
Volume 17,013
Average $0.330
Sold $2,197
Volume 6,704
Average $0.328
Net $3,412
Volume 10,309
 



294ever wrote:

Pretty low volume today. Although I agree there is the FOMO factor at play what I see is investors cautiously waiting for Data. Nobody is gobbling up shares here. I'm confident data will be good but not convinced management can run this to the end zone in a timely fashion. It would also appear that this is the markets sentiment judging by the less than overwhelming volume we've seen here over the course of the week. 

I pray that My Gut and every shred of logical thought I have is wrong and this thing works out.

GLTA
 



<< Previous
Bullboard Posts
Next >>